{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T18:54:21Z","timestamp":1772045661955,"version":"3.50.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2016,10,31]],"date-time":"2016-10-31T00:00:00Z","timestamp":1477872000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs R D"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1007\/s40268-016-0149-5","type":"journal-article","created":{"date-parts":[[2016,10,31]],"date-time":"2016-10-31T13:37:05Z","timestamp":1477921025000},"page":"369-376","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Distinct Glucose-Lowering Mechanisms of Ipragliflozin Depending on Body Weight Changes"],"prefix":"10.1007","volume":"16","author":[{"given":"Eiji","family":"Kutoh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teruma","family":"Murayama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asuka","family":"Wada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsuru","family":"Hirate","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,10,31]]},"reference":[{"issue":"4","key":"149_CR1","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1210\/er.2010-0029","volume":"32","author":"MA Abdul-Ghani","year":"2011","unstructured":"Abdul-Ghani MA, Norton L, Defronzo RA. Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes. Endocr Rev. 2011;32(4):515\u201331.","journal-title":"Endocr Rev."},{"issue":"6","key":"149_CR2","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1016\/j.clinthera.2015.03.004","volume":"37","author":"K Whalen","year":"2015","unstructured":"Whalen K, Miller S, Onge ES. The role of sodium-glucose co-transporter 2 inhibitors in the treatment of type 2 diabetes. Clin Ther. 2015;37(6):1150\u201366.","journal-title":"Clin Ther."},{"issue":"1","key":"149_CR3","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1463-1326.2011.01511.x","volume":"14","author":"RA DeFronzo","year":"2012","unstructured":"DeFronzo RA, Davidson JA, Del Prato S. The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia. Diabetes Obes Metab. 2012;14(1):5\u201314.","journal-title":"Diabetes Obes Metab."},{"issue":"6 Suppl 1","key":"149_CR4","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/S1262-3636(14)72689-8","volume":"40","author":"AJ Scheen","year":"2014","unstructured":"Scheen AJ, Paquot N. Metabolic effects of SGLT-2 inhibitors beyond increased glucosuria: a review of the clinical evidence. Diabetes Metab. 2014;40(6 Suppl 1):S4\u201311.","journal-title":"Diabetes Metab."},{"issue":"5","key":"149_CR5","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.jash.2014.02.003","volume":"8","author":"RV Oliva","year":"2014","unstructured":"Oliva RV, Bakris GL. Blood pressure effects of sodium-glucose co-transport 2 (SGLT2) inhibitors. J Am Soc Hypertens. 2014;8(5):330\u20139.","journal-title":"J Am Soc Hypertens."},{"issue":"4","key":"149_CR6","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1517\/17425255.2015.1009893","volume":"11","author":"MS Hedrington","year":"2015","unstructured":"Hedrington MS, Davis SN. Ipragliflozin, a sodium-glucose cotransporter 2 inhibitor, in the treatment of type 2 diabetes. Expert Opin Drug Metab Toxicol. 2015;11(4):613\u201323.","journal-title":"Expert Opin Drug Metab Toxicol."},{"issue":"5","key":"149_CR7","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1007\/s40265-014-0204-x","volume":"74","author":"RM Poole","year":"2014","unstructured":"Poole RM, Dungo RT. Ipragliflozin: first global approval. Drugs. 2014;74(5):611\u20137.","journal-title":"Drugs."},{"issue":"1","key":"149_CR8","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.pharmthera.2013.04.003","volume":"139","author":"E Kurosaki","year":"2013","unstructured":"Kurosaki E, Ogasawara H. Ipragliflozin and other sodium-glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: preclinical and clinical data. Pharmacol Ther. 2013;139(1):51\u20139.","journal-title":"Pharmacol Ther."},{"issue":"4","key":"149_CR9","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1111\/jdi.12156","volume":"5","author":"A Kashiwagi","year":"2014","unstructured":"Kashiwagi A, Kazuta K, Yoshida S, Nagase I. Randomized, placebo-controlled, double-blind glycemic control trial of novel sodium-dependent glucose cotransporter 2 inhibitor ipragliflozin in Japanese patients with type 2 diabetes mellitus. J Diabetes Investig. 2014;5(4):382\u201391.","journal-title":"J Diabetes Investig."},{"issue":"1","key":"149_CR10","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1507\/endocrj.EJ14-0335","volume":"62","author":"M Takahara","year":"2015","unstructured":"Takahara M, Shiraiwa T, Matsuoka TA, Katakami N, Shimomura I. Ameliorated pancreatic \u03b2 cell dysfunction in type 2 diabetic patients treated with a sodium-glucose cotransporter 2 inhibitor ipragliflozin. Endocr J. 2015;62(1):77\u201386.","journal-title":"Endocr J."},{"issue":"7","key":"149_CR11","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1055\/s-0035-1569454","volume":"66","author":"E Kutoh","year":"2016","unstructured":"Kutoh E, Wada A, Murayama T, Hirate M. Ipragliflozin as an initial therapy in drug na\u00efve subjects with type 2 diabetes. Drug Res (Stuttg). 2016;66(7):345\u201350.","journal-title":"Drug Res (Stuttg)."},{"key":"149_CR12","doi-asserted-by":"crossref","unstructured":"Kutoh E, Wada A, Hirate M. Distinct glucose lowering mechanisms of ipragliflozin depending on body weight change. American Diabetes Association Scientific Meeting 2016 [1186-P].","DOI":"10.1007\/s40268-016-0149-5"},{"issue":"6 Suppl 1","key":"149_CR13","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1016\/S1262-3636(14)72693-X","volume":"40","author":"S Halimi","year":"2014","unstructured":"Halimi S, Verg\u00e8s B. Adverse effects and safety of SGLT-2 inhibitors. Diabetes Metab. 2014;40(6 Suppl 1):S28\u201334.","journal-title":"Diabetes Metab."},{"issue":"6","key":"149_CR14","doi-asserted-by":"crossref","first-page":"753","DOI":"10.4158\/EP161292.PS","volume":"22","author":"Y Handelsman","year":"2016","unstructured":"Handelsman Y, Henry RR, Bloomgarden ZT, Dagogo-Jack S, DeFronzo RA, Einhorn D, Ferrannini E, Fonseca VA, Garber AJ, Grunberger G, LeRoith D, Umpierrez GE, Weir MR. American Association of Clinical Endocrinologists and American College of Endocrinology position statement on the association of SGLT-2 inhibitors and diabetic ketoacidosis. Endocr Pract. 2016;22(6):753\u201362.","journal-title":"Endocr Pract."},{"issue":"4","key":"149_CR15","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1111\/jdi.12471","volume":"7","author":"A Kashiwagi","year":"2016","unstructured":"Kashiwagi A, Yoshida S, Nakamura I, Kazuta K, Ueyama E, Takahashi H, Satomi H, Kosakai Y, Kawamuki K. Efficacy and safety of ipragliflozin in Japanese patients with type 2 diabetes stratified by body mass index: a subgroup analysis of five randomized clinical trials. J Diabetes Investig. 2016;7(4):544\u201354. doi: 10.1111\/jdi.12471 .","journal-title":"J Diabetes Investig."},{"key":"149_CR16","doi-asserted-by":"crossref","unstructured":"Committee of the Japan Diabetes Society on the diagnostic criteria of diabetes mellitus. Report of the committee on the classification and diagnostic criteria of diabetes mellitus. J Diabetes Investig. 2010;1(5):212\u2013228.","DOI":"10.1111\/j.2040-1124.2010.00074.x"},{"issue":"1","key":"149_CR17","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.nut.2007.10.008","volume":"24","author":"Y Ma","year":"2008","unstructured":"Ma Y, Olendzki BC, Merriam PA, Chiriboga DE, Culver AL, Li W, H\u00e9bert JR, Ockene IS, Griffith JA, Pagoto SL. A randomized clinical trial comparing low-glycemic index versus ADA dietary education among individuals with type 2 diabetes. Nutrition. 2008;24(1):45\u201356.","journal-title":"Nutrition."},{"issue":"2","key":"149_CR18","doi-asserted-by":"crossref","first-page":"88","DOI":"10.3109\/07435800.2014.952743","volume":"40","author":"E Kutoh","year":"2015","unstructured":"Kutoh E, Kaneoka N, Hirate M. Alogliptin: a new dipeptidyl peptidase-4 inhibitor with potential anti-atherogenic properties. Endocr Res. 2015;40(2):88\u201396.","journal-title":"Endocr Res."},{"issue":"11","key":"149_CR19","first-page":"1985","volume":"47","author":"RR Little","year":"2001","unstructured":"Little RR, Rohlfing CL, Wiedmeyer HM, Myers GL, Sacks DB. Goldstein DE; NGSP Steering Committee. The national glycohemoglobin standardization program: a five-year progress report. Clin Chem. 2001;47(11):1985\u201392.","journal-title":"Clin Chem."},{"issue":"7","key":"149_CR20","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1007\/s00125-004-1453-0","volume":"47","author":"K Miedema","year":"2004","unstructured":"Miedema K. Towards worldwide standardisation of HbA1c determination. Diabetologia. 2004;47(7):1143\u20138.","journal-title":"Diabetologia."},{"issue":"7","key":"149_CR21","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1007\/BF00280883","volume":"28","author":"DR Matthews","year":"1985","unstructured":"Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF. Turner RC Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28(7):412\u20139.","journal-title":"Diabetologia."},{"key":"149_CR22","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ejphar.2014.01.040","volume":"727","author":"M Yokono","year":"2014","unstructured":"Yokono M, Takasu T, Hayashizaki Y, Mitsuoka K, Kihara R, Muramatsu Y, Miyoshi S, Tahara A, Kurosaki E, Li Q, Tomiyama H, Sasamata M, Shibasaki M, Uchiyama Y. SGLT2 selective inhibitor ipragliflozin reduces body fat mass by increasing fatty acid oxidation in high-fat diet-induced obese rats. Eur J Pharmacol. 2014;727:66\u201374.","journal-title":"Eur J Pharmacol."},{"issue":"6","key":"149_CR23","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1507\/endocrj.EJ15-0749","volume":"63","author":"C Yamamoto","year":"2016","unstructured":"Yamamoto C, Miyoshi H, Ono K, Sugawara H, Kameda R, Ichiyama M, Yamamoto K, Nomoto H, Nakamura A, Atsumi T. Ipragliflozin effectively reduced visceral fat in Japanese patients with type 2 diabetes under adequate diet therapy. Endocr J. 2016;63(6):589\u201396.","journal-title":"Endocr J."},{"issue":"7","key":"149_CR24","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1002\/bdd.1909","volume":"35","author":"Y Chino","year":"2014","unstructured":"Chino Y, Samukawa Y, Sakai S, Nakai Y, Yamaguchi J, Nakanishi T, Tamai I. SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria. Biopharm Drug Dispos. 2014;35(7):391\u2013404.","journal-title":"Biopharm Drug Dispos."},{"issue":"22","key":"149_CR25","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE, EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117\u201328.","journal-title":"N Engl J Med."},{"issue":"2","key":"149_CR26","doi-asserted-by":"crossref","first-page":"E255","DOI":"10.1152\/ajpendo.00416.2010","volume":"300","author":"A Giacca","year":"2011","unstructured":"Giacca A, Xiao C, Oprescu AI, Carpentier AC, Lewis GF. Lipid-induced pancreatic \u03b2-cell dysfunction: focus on in vivo studies. Am J Physiol Endocrinol Metab. 2011;300(2):E255\u201362.","journal-title":"Am J Physiol Endocrinol Metab."},{"issue":"8","key":"149_CR27","doi-asserted-by":"crossref","first-page":"863","DOI":"10.2337\/diab.44.8.863","volume":"44","author":"RH Unger","year":"1995","unstructured":"Unger RH. Lipotoxicity in the pathogenesis of obesity-dependent NIDDM. Genetic and clinical implications. Diabetes. 1995;44(8):863\u201370.","journal-title":"Diabetes."},{"issue":"3","key":"149_CR28","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.beem.2016.06.006","volume":"30","author":"S Lallukka","year":"2016","unstructured":"Lallukka S, Yki-J\u00e4rvinen H. Non-alcoholic fatty liver disease and risk of type 2 diabetes. Best Pract Res Clin Endocrinol Metab. 2016;30(3):385\u201395.","journal-title":"Best Pract Res Clin Endocrinol Metab."}],"container-title":["Drugs in R&D"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-016-0149-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40268-016-0149-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-016-0149-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,25]],"date-time":"2017-06-25T02:26:48Z","timestamp":1498357608000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40268-016-0149-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10,31]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["149"],"URL":"https:\/\/doi.org\/10.1007\/s40268-016-0149-5","relation":{},"ISSN":["1174-5886","1179-6901"],"issn-type":[{"value":"1174-5886","type":"print"},{"value":"1179-6901","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10,31]]}}}